comprehensive -WSS

comprehensive

author：explore 2025-10-01 20:14:08 - browse：5536

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Criminal prosecution for violating HIPAA: an emerging threat

hotspot

WSS

Solving academic medical centers' existential crisis

Washington mulls new rules to avert another Change Healthcare

Scientists boost immune system in aging mice by making it youthful

Food as medicine: Medically tailored meals may get standardized

Washington mulls new rules to avert another Change Healthcare

Abortion pill Supreme Court ruling could impact entire drug industry

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Drug repurposing or repositioning? The language matters

Cytokinetics CEO stresses company can launch heart drug on its own

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Virginia high school admissions case could be legal follow

Readers respond to H5N1 and livestock movements, and more

ChatGPT in medicine: STAT answers readers' burning questions

With measles on the rise, a personal story of a devastating disease

Wildfire smoke exposes gaps in outdoor worker protections

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Wikipedia

Merck drug for rare lung condition set for approval in U.S.

Steward Health Care has deal to sell doctor network to UnitedHealth

Roche subsidiary Foundation Medicine opens new headquarters

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Data integrity in scientific journals requires "effort" by publishers, institutions

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

hotspot

explore

hotspot

hotspot